Skip to main content

Table 1 Number and reason for drop outs at each visit

From: A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

Clinical visit (n)Drop out (n)
Screening (n = 31)Failed screening (n = 2)
Lost to follow up (n = 1)
Withdrawal of consent (n = 1)
Baseline (n = 27)No longer eligible (n = 1)
Withdrawal of consent (n = 1)
3 months (n = 25)Intolerable menopausal symptoms (n = 1)
No improvement in symptoms (n = 2)
6 months (n = 22)No improvement in symptoms (n = 1)
9 months (n = 21)Wishing to conceive (n = 1)
No improvement of symptoms (n = 1)
12 months (n = 19)Wishing to conceive (n = 1)
No improvement of symptoms (n = 1)
15 months (n = 17)Intolerable menopausal symptoms (n = 2)
18 months (n = 15)Intolerable menopausal symptoms (n = 1)
Lost to follow up (n = 1)
24 months (n = 13)No further drop outs